In asthma patients with B16 Arg/Arg and B16 Gly/Gly genotypes, LABA/ICS improved airway function when compared with ICS. Patients should continue to be treated with LABA/ICS irrespective of B16 genotype - The Lancet http://bit.ly/82QEFb
FDA panel recommends against approving omalizumab (Xolair) for severe asthma in children aged 6-11 years - see the AAAAI/ACAAI statement http://bit.ly/5npJgt
Recognize 'discords' of 'immune-system symphonic orchestra', brighten up dark and winding road of immunodeficiencies http://bit.ly/OqOTy
Never Underestimate the Power of a Neutrophil http://bit.ly/7JxmOt
Explore Google images through Swirl interface http://bit.ly/4yGMvi) - See urticaria example http://bit.ly/22hH4i
Medical news tweets are not research articles - they are 140-character messages - please always go to the original source, links, etc. Tweets and links do not represent endorsement, approval or support. Image source: OpenClipArt.org, public domain.
Follow me on Twitter: